Tammy Sharon

Director Strategy And Business Operations at Pluri

Tammy Sharon has extensive work experience in various roles and industries. Tammy began their career in 2006 at Rambam Medical Center as an Immunology Lab specialist, where they were responsible for conducting tissue classification tests for bone marrow transplants. Tammy then joined Intel Corporation in 2008 as a Project Manager, leading and managing new labs projects as well as coordinating with multiple stakeholders. In 2012, Tammy worked as an HR specialist at Protalix Biotherapiutics. Tammy later joined Pluri in 2013, where they held several roles including Investor and Public Relations Manager, Corporate Planning Manager, Senior Manager of Corporate Projects, and Director of Strategy and Business Operations. Tammy is currently a member of WE@HealthTech since 2022. Throughout their career, they have demonstrated strong project management skills, strategic planning abilities, and expertise in various lab techniques.

Tammy Sharon has a diverse education history. Tammy completed their Executive Leadership Development program at Stanford University Graduate School of Business in 2022. Prior to that, they obtained an MBA from Technion - Israel Institute of Technology from 2007 to 2009, with a focus on Business. Tammy also holds an M.Sc. in Biology from The Hebrew University of Jerusalem, which they earned from 2002 to 2005. Additionally, they obtained a certification in hydrotherapy from Wingate Institute in 2003 and 2004. Tammy began their academic journey with a B.Sc. in Biotechnology from Tel-Hai College, which they completed from 1998 to 2001.

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Pluri

3 followers

Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.


Headquarters

Haifa, Israel

Employees

51-200

Links